Direct-acting antivirals (DAA) have revolutionized the treatment of patients with chronic
hepatitis C virus (HCV) infection, possibly leading to HCV elimination by 2030 as endorsed …

Although hepatitis C virus (HCV) RNA may be eliminated from blood circulation by direct-
acting antivirals (DAA) therapy as assessed by real-time polymerase chain reaction (PCR) …

Background and Aims Hepatitis B virus (HBV) reactivation is a serious condition and has
been extensively described in chemotherapeutic immunosuppressive population. However …

Hepatitis B virus (HBV) infection is a significant global public health threat with variable
geographical distribution. Chronic infection with HBV could be complicated by chronic …

Hepatitis B (HBV) reactivation was observed to be more than 10% in patients receiving
interferon-based therapy for hepatitis C (HCV) co-infection. At present, when direct-acting …

The first direct-acting antiviral (DAA) medications were approved for the treatment of chronic
hepatitis C virus (HCV) in 2011. Later, the appearance of novel DAAs had revolutionized the …

Sofosbuvir and Daclatasvir are among the direct‐acting antiviral (DAA) medications
prescribed for the treatment of chronic hepatitis C (CHC) virus infection as combination …

ABSTRACT Introduction Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections share
common routes of transmission. HBV/HCV coinfection can lead to interactions affecting …

Background In 2017, the hepatitis C treatment regimens sofosbuvir/velpatasvir/voxilaprevir
(SOF/VEL/VOX) and glecaprevir/pibrentasvir (G/P) received approval from the US Food and …

Background and aim Hepatitis C virus (HCV)–HBV coinfection is a significant health
problem with rapid progression of liver disease without precise diagnosis and treatment. We …